Is Enoxaparin Sodium Injection (Lovenox) in shortage?
Enoxaparin Sodium Injection is listed by FDA as being discontinued by at least one maker (updated Oct 20, 2026).
Every listed package
FDA tracks shortages per package. What each maker reports, most recently updated first:
- Lovenox, Injection, 40 mg/.4 mL (NDC 0075-0620-40)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-633-1610
- Lovenox, Injection, 60 mg/.6 mL (NDC 0075-0621-60)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 80 mg/.8 mL (NDC 0075-0622-80)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 300 mg/3 mL (NDC 0075-0626-03)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 120 mg/.8 mL (NDC 0075-2912-01)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 150 mg/1 mL (NDC 0075-2915-01)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 30 mg/.3 mL (NDC 0075-8013-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 40 mg/.4 mL (NDC 0075-8014-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 60 mg/.6 mL (NDC 0075-8016-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 80 mg/.8 mL (NDC 0075-8018-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 100 mg/1 mL (NDC 0075-8020-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 120 mg/.8 mL (NDC 0075-8022-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 150 mg/1 mL (NDC 0075-8025-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Lovenox, Injection, 300 mg/3 mL (NDC 0075-8030-01)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 30 mg/.3 mL (NDC 0955-1003-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 40 mg/.4 mL (NDC 0955-1004-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 60 mg/.6 mL (NDC 0955-1006-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 80 mg/.8 mL (NDC 0955-1008-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 120 mg/.8 mL (NDC 0955-1012-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 150 mg/1 mL (NDC 0955-1015-10)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
- Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01)
Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
Maker contact: 800-631-1610
FDA recalls of Enoxaparin Sodium
Recalls can cause or worsen a shortage. These FDA drug recalls share an active ingredient with Enoxaparin Sodium Injection:
- Cardinal Health Inc. recalls Enoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled syringes further packaged in bags of 5
- CARDINAL HEALTHCARE recalls Enoxaparin Sodium Injection, USP, 150MG/ML Single-Dose Syringes with Automatic Safety Device, For Subcutaneous
- Sanofi-Aventis U.S. LLC recalls Enoxaparin Sodium, Injection 120 mg/0.8 mL, pre-filled, packaged in 10-count cartons, Rx Only, Winthrop US., a business
Enoxaparin Sodium Injection shortage questions
Is Enoxaparin Sodium Injection (Lovenox) in shortage?
Enoxaparin Sodium Injection is listed by FDA as being discontinued by at least one maker (updated Oct 20, 2026).
What should I do if I can’t get Enoxaparin Sodium Injection?
Don’t stop or ration it on your own. Ask your pharmacist whether another strength, package size or maker is in stock, and ask your prescriber about an alternative if none is.
Source: FDA Drug Shortages Database via openFDA. FDA notes that openFDA data is unvalidated and should not be used to make decisions about medical care; ask your pharmacist or prescriber before changing any medication. FDA Drug Shortages Database.